ArriVent BioPharma, Inc. (AVBP)
NASDAQ: AVBP · Real-Time Price · USD
27.45
+0.86 (3.23%)
Nov 22, 2024, 4:00 PM EST - Market closed
ArriVent BioPharma Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for ArriVent BioPharma stock have an average target of 36.8, with a low estimate of 35 and a high estimate of 39. The average target predicts an increase of 34.06% from the current stock price of 27.45.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for AVBP stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
---|---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
Buy | 0 | 0 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 4 | 4 | 5 | 5 | 5 | 5 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $36 | Strong Buy | Reiterates | $36 | +31.15% | Nov 15, 2024 |
Citigroup | Citigroup | Strong Buy Maintains $30 → $36 | Strong Buy | Maintains | $30 → $36 | +31.15% | Sep 11, 2024 |
Oppenheimer | Oppenheimer | Buy Reiterates $35 → $39 | Buy | Reiterates | $35 → $39 | +42.08% | Sep 10, 2024 |
Goldman Sachs | Goldman Sachs | Strong Buy Maintains $28 → $38 | Strong Buy | Maintains | $28 → $38 | +38.43% | Sep 10, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $30 → $36 | Strong Buy | Maintains | $30 → $36 | +31.15% | Sep 10, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.26
from -32.38
EPS Next Year
-2.84
from -3.26
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | n/a | n/a | 10.2M | ||
Avg | n/a | n/a | 3.3M | ||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
EPS Forecast
EPS | 2024 | 2025 | 2026 |
---|---|---|---|
High | -2.86 | -0.45 | -2.14 |
Avg | -3.26 | -2.84 | -3.28 |
Low | -4.17 | -4.09 | -4.27 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 |
---|---|---|---|
High | - | - | - |
Avg | - | - | - |
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.